With AngioDynamics set to report second quarter results before the Jan. 6 open, seven leading Wall Street analysts have adjusted their full-year revenue and earnings per share estimates. The consensus revenue forecast now stands at $275.3 million, up 1.1% from prior estimates, while EPS projections have been nudged higher to $1.12, reflecting greater confidence in margin improvement initiatives. Analysts from Stifel and Jefferies increased their price targets by 5% and 7%, respectively, citing stronger Med Tech orders in December and a stabilizing backlog in Europe as key catalysts.

AngioDynamics’ Med Tech division continues to outpace the broader company, delivering year-over-year revenue growth of 14% in Q1 and accounting for 46% of total sales. Thrombus management products have seen a 22% sales surge, led by AlphaVac pump systems selling 3,400 units in the last quarter. The NanoKnife platform recorded a 30% uptick in procedure volume, pushing global unit deployment past 1,200. Atherectomy device Auryon captured 12% market share in the U.S. by December, up from 8% six months earlier, driven by expansion in three new high-volume vascular centers.

Recent peer-reviewed studies presented at the Vascular Interventional Advances conference showed AlphaVac reducing procedure times by an average of 18 minutes versus competing devices, while NanoKnife demonstrated a 15% higher local tumor control rate in pancreatic cancer lesions under 3cm. These findings are expected to bolster hospital formularies and support reimbursement negotiations. Management noted in a December investor presentation that inclusion of NanoKnife in two major oncology guidelines could add $25 million in incremental annual revenue by year-end 2026.

While Med Tech excels, the legacy Med Device segment remains a drag, posting flat sales and 200 basis points of gross margin contraction due to pricing pressures on vessel closure products. Overall company gross margin expanded by 150 basis points to 62.3% in Q1, but operating margin of 11.8% fell short of the 13% target as SG&A expenses rose 7% year-over-year to support product launches. Management has outlined cost-synergy plans aimed at saving $12 million annually by consolidating two manufacturing sites in the second half of 2026.